Insider buying last 90 days
No open-market insider purchases were filed for LLY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LLY insider filing, plotted on the chart in Gekko.Open LLY in Gekko
NYSE: LLY
Eli Lilly (LLY) Stock Analysis & Forecast
$1,152.22+0.09 (0.0%)
Close on Sep 18, 2026. Page updated Sep 19, 9:14 pm ET.
Gekko Brief
AI summaryEli Lilly closes at $1152.22, sitting between its 50-day average of $1177.32 and 200-day average of $1066.34. The GekkoIndex reads 61, placing the stock in the Accumulation zone, though the reading has slipped 6.4 points over the past five sessions. The price sits 15.7% above Gekko Fair Value of $995.95, a gap that bears watching.
This week's news centers on the incretin franchise and regulatory progress. The FDA approved Lilly's breast cancer drug combination, while attention also turns to a September 30 mid-stage data readout for the two-drug obesity combination eloraTZP, which commentary ties to the company's valuation. Elsewhere, a rival's failed cholesterol drug trial has raised questions for similar experimental compounds across the industry, including Lilly's, and a report flagged unapproved versions of Lilly's experimental drug Retatrutide being sold online. A partnership between Twist Bioscience and Lilly's TuneLab platform was also announced, aimed at antibody data services for drug discovery.
Over the next 20 trading days, the next earnings date falls outside that window, on 29 October. Seasonally, this calendar stretch has averaged a 5.2% gain over five years, rising in five of them. Analyst coverage shows 19 buy ratings, 1 hold, and 1 sell among 21 firms, with a consensus target of $1324.87, implying 15% upside. No insider, Congress, or unusual options activity appears in the recent windows, though three billionaire holders and one trailblazer holder are noted.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $1,152.22200-day averageGekko Fair Value $995.95
Key stats
- Market cap
- $1.09T
- P/E ratio
- 38.2
- Forward P/E
- 24.1
- EPS, TTM
- $30.19
- Revenue, TTM
- $79.67B
- Profit margin
- 33.5%
- Dividend yield
- 0.57%
- Beta
- 0.50
- Volume
- 4.32M avg 2.33M
- 1-year return
- +51.6%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±5.9%
- 50-day average
- $1,177.32
- 200-day average
- $1,066.34
- Next earnings
- Oct 29
- Shares outstanding
- 891.7M
Eli Lilly swing-trade checklist
Eli Lilly scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $1152.22 sits between the 50-day ($1177.32) and 200-day ($1066.34) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
61, Accumulation
Reading 61 is in the Accumulation zone.
See the GekkoIndex - Fair valueheadwind
15.7% above
Price is 15.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.2% on average
From this point in the calendar, the next 20 trading days averaged +5.2% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Eli Lilly stock chart and price history
Eli Lilly closed at $1,152.22 on Sep 18, 2026, +51.6% over the past year, inside a 52-week range of $712.05 to $1,292.65.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −10.0%
- 3 months
- +4.9%
- 6 months
- +25.6%
- 1 year
- +51.6%
The full LLY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LLY in Gekko
Follow Eli Lilly through every session
Put LLY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LLY in GekkoFree for 7 days. No credit card required.
About Eli Lilly
Eli Lilly develops and sells medicines for patients worldwide, with a name most associated with its long-running diabetes care line. Its treatments span insulin products such as Basaglar, Humalog, and Humulin, alongside type 2 diabetes therapies including Jardiance, Trajenta, and Trulicity, making this area a central part of its business.
Beyond diabetes, the company markets medicines across several other areas of health. In oncology it offers treatments like Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio for various cancers, while Olumiant and Taltz address autoimmune and inflammatory conditions. It also supplies medicines for neurological and pain-related conditions, including Cymbalta, Emgality, and Zyprexa, along with Cialis, Forteo, and antibody treatments developed for COVID-19. The company works with a range of partners, among them Incyte, Boehringer Ingelheim, AbCellera, Junshi Biosciences, and Regor Therapeutics, to support its research and development efforts.
Eli Lilly's shares are listed on the NYSE under the ticker LLY.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- lilly.com
Eli Lilly GekkoIndex: the smart money zone
Eli Lilly’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61, in the Accumulation zone, down 6.4 points over five sessions.
61Accumulation
Down 6.4 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 32 | +3.1% | +7.1% |
| Accumulation (current zone) | 187 | +0.8% | +3.6% |
| Neutral | 365 | +0.1% | +1.2% |
| Distribution | 67 | +1.2% | +1.5% |
| Selling | 11 | +2.4% | +4.6% |
Average LLY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the LLY price, zone by zone.Track LLY in Gekko
Is Eli Lilly stock overvalued? Gekko Fair Value
Eli Lilly trades 15.7% above Gekko Fair Value of $995.95, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Eli Lilly shares are worth, recalculated every trading day.
$995.95
Gekko Fair Value, Sep 19, 2026
15.7% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open LLY in Gekko
Eli Lilly insider and Congress trading
No open-market insider purchases were filed for Eli Lilly, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LLY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LLY, plotted on the chart in Gekko.Open LLY in Gekko
Buybacks
Eli Lilly has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.60B
- As a share of market cap
- 0.15%
- Trailing four quarters
- $6.17B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
4of the funds Gekko tracks hold LLY.
1added3opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Eli Lilly earnings: next date and track record
Eli Lilly reports on Oct 29, 2026 (39 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 29, 2026
39 days away
- EPS estimate
- $9.85
- Revenue estimate
- $22.19B
7 of 8reports beat the EPS estimate
±8.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Eli Lilly reported a strong Q2 2026 with 48% revenue growth versus Q2 2025, driven primarily by incretin medicines (Mounjaro and Zepbound/Foundayo) and broad strength across Oncology, Immunology, and Neuroscience. Management raised full-year guidance and highlighted expanded commercial access (including Medicare Bridge and PBM access), meaningful international launches and approvals (Foundayo approvals in UAE, Saudi Arabia, Mexico; EU approvals for other medicines), and a robust R&D pipeline with several positive Phase 3 readouts (notably retatrutide TRIUMPH program and orforglipron ACHIEVE trials). The company emphasized continued investment in marketing and R&D, strong gross and non-GAAP margins, and progress on registering new medicines (retatrutide planned U.S. submission Q1 2027). In Q&A, management reiterated confidence in launches (Foundayo, Mounjaro), consumer-facing initiatives (LillyDirect), international expansion, and M&A strategy, while addressing questions on pricing, reimbursement, regulatory pathways (including ongoing litigation and CMC work for retatrutide BLA classification), and competitive dynamics.
- Guidance
- Raised full-year revenue guidance by approximately $2.5 billion (management noted an upward revision to 2026 guidance). Retatrutide filing expected by Q1 2027 (BLA pathway targeted). Lilly expects continued growth but flagged quarter-to-quarter seasonality, U.S. rebate/discount estimate adjustments, and that some one-time items in earlier quarters will not repeat.
- Risks flagged
- Regulatory uncertainty and active litigation regarding BLA classification for retatrutide; remaining chemistry, manufacturing and controls (CMC) work required prior to filing; competition from other incretin makers (oral and injectable competitors like Novo); potential pricing pressure (U.S. price declines and reimbursement dynamics); generic launches (e.g., semaglutide generics in certain markets); reimbursement timing OUS for diabetes indications; supply constraints in some markets for competitor generics that could shift dynamics; seasonality effects and prior-period rebate/discount adjustments that affect comparability.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $8.38 est $6.01 | $22.97B est $20.69B | +6.8% |
| Apr 30, 2026 | $8.55 est $7.25 | $19.80B est $17.82B | +13.2% |
| Feb 4, 2026 | $7.54 est $6.91 | $19.29B est $17.94B | +1.7% |
| Oct 30, 2025 | $7.02 est $5.69 | $17.60B est $16.05B | +6.1% |
| Aug 7, 2025 | $6.31 est $5.60 | $15.56B est $14.70B | −16.2% |
| May 1, 2025 | $3.34 est $3.26 | $12.73B est $12.67B | −8.4% |
| Feb 6, 2025 | $5.32 est $5.03 | $13.53B | +4.3% |
| Oct 30, 2024 | $1.18 est $1.47 | $11.44B est $12.10B | −8.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Eli Lilly stock forecast and analyst price targets
Analysts’ average 12-month price target for Eli Lilly is $1,324.87, +15.0% from the last close, from 21 firms rating the stock in the last 90 days.
$1,324.87consensus 12-month target, +15.0% from the last close
Now $1,152.22Avg $1,324.87
Low $940High $1,600
Each firm’s latest rating in the last 90 days: 21 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Guggenheim | $1,284 | +11.4% |
| Sep 16 | Leerink Partners | — | — |
| Sep 15 | Berenberg Bank | $1,400 | +21.5% |
| Sep 14 | Berenberg Bank | $1,400 | +21.5% |
| Sep 14 | RBC Capital | $1,500 | +30.2% |
+3.6%average 20-day move after past Accumulation readings
+5.2%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Eli Lilly seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Eli Lilly averaged +5.2% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.5% | 2 of 5 |
| Next 10 trading days | +0.8% | 2 of 5 |
| Next 15 trading days | +4.1% | 5 of 5 |
| Next 20 trading days | +5.2% | 5 of 5 |
| Next 30 trading days | +6.2% | 3 of 5 |
For scale, LLY’s typical 20-trading-day move in either direction is about 5.9%.
Eli Lilly market cap and key statistics
Eli Lilly’s market cap is $1.09T, with a P/E ratio of 38.2 and revenue of $79.67B over the last twelve months.
Valuation
- Market cap
- $1.09T
- P/E ratio
- 38.2
- Forward P/E
- 24.1
- EPS, TTM
- $30.19
- Gekko Fair Value
- $995.95
Trading
- Volume
- 4.32M
- Avg volume, 20 days
- 2.33M
- 52-week high
- $1,292.65
- 52-week low
- $712.05
- Shares outstanding
- 891.7M
Financials
- Revenue, TTM
- $79.67B
- Profit margin
- 33.5%
- Return on equity
- 102.3%
- Quarterly earnings growth, YoY
- +26.2%
Risk and income
- Beta
- 0.50
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±5.9%
- Dividend yield
- 0.57%
Eli Lilly stock news this week
Coverage of Eli Lilly this week reads positive: 6 positive, 2 neutral and 1 negative headlines.
- Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?24/7 Wall Street, Sep 18
- US FDA approves Lilly's breast cancer drug comboReuters, Sep 18
- Better Buy for Cautious Investors: Eli Lilly vs CostcoThe Motley Fool, Sep 18
- A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) TooInsider Monkey, Sep 17
- Companies illegally selling unapproved Eli Lilly weight loss drug Retatrutide onlineCBS News, Sep 17
- This Trend is Excellent News for Eli Lilly and Its InvestorsThe Motley Fool, Sep 17
Eli Lilly peers
Eli Lilly’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| JNJJohnson & Johnson | Neutral | 2.7% below |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| AZNAstraZeneca | Neutral | 41.0% below |
| PFEPfizer | Neutral | 9.8% below |
| VRTXVertex Pharmaceuticals | Accumulation | 9.7% above |
A peer links to its own page where one exists.
Eli Lilly stock FAQ
What is Eli Lilly’s market cap?
Eli Lilly’s market cap is $1.09T at the Sep 18, 2026 close of $1,152.22, with 891.7M shares outstanding. The shares trade on a P/E ratio of 38.2.
What is the Eli Lilly stock forecast?
The consensus analyst 12-month price target for Eli Lilly is $1,324.87, +15.0% from the last close. Of the 21 firms that rated the stock in the last 90 days, 19 rate it a buy, 1 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Eli Lilly stock overvalued or undervalued?
On Gekko’s estimate Eli Lilly is overvalued: the Sep 18, 2026 close of $1,152.22 is 15.7% above Gekko Fair Value of $995.95. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Eli Lilly report earnings next?
Eli Lilly is expected to report on Oct 29, 2026 (39 days away). Analysts expect earnings of $9.85 per share on revenue of $22.19B. Eli Lilly beat the earnings estimate in 7 of its last 8 reports, moving 8.1% on average across the report.
What is Eli Lilly’s 52-week high and low?
Eli Lilly’s 52-week high is $1,292.65 and its 52-week low is $712.05; it closed at $1,152.22 on Sep 18, 2026, +51.6% over the past year.
Is Eli Lilly stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Eli Lilly the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.